Comparison of Occupational Noise Exposure Assessment Methods: A Systematic Review
N Makaruse, M Maslin, Z Shai-Campbell - Ear and Hearing, 2024 - journals.lww.com
Objectives: The purpose of this systematic review of publications was to evaluate existing
evidence on the accuracy and precision of alternative occupational noise assessment …
evidence on the accuracy and precision of alternative occupational noise assessment …
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
Multiple myeloma (MM) is the main indication for autologous stem cell transplantation
(ASCT). Novel supportive therapies (eg, granulocyte colony-stimulating factor) have …
(ASCT). Novel supportive therapies (eg, granulocyte colony-stimulating factor) have …
Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors—a questionnaire study
Purpose This study aims to delineate G-CSF treatment practices, assess decision criteria,
and measure their implementation in ambulatory settings for patients with breast (BC), lung …
and measure their implementation in ambulatory settings for patients with breast (BC), lung …
Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC)
B Kazi, PK Mandal, S Mitra, I Rumani, S Mandal… - 2024 - researchsquare.com
Background: Consolidation therapy with high dose cytarabine (HIDAC) for Acute Myeloid
Leukemia (AML) is associated with significant neutropenia, resultant infections and …
Leukemia (AML) is associated with significant neutropenia, resultant infections and …
[PDF][PDF] A Systematic Review to Compare Costs and Outcomes of Pharmacoeconomic Evaluations of Conventional and Biosimilars G-CSFs
Introduction: The presence of biosimilars in the field of oncology is regarded as a key
approach to attain susta inable healthcare. Gra nulocyte colony-stimulating fa ctor (G-CSF) …
approach to attain susta inable healthcare. Gra nulocyte colony-stimulating fa ctor (G-CSF) …
[PDF][PDF] Drug Class Update with New Drug Evaluation: Colony Stimulating Factors
D Moretz - 2021 - orpdl.org
Conclusions:• No new high-quality comparative evidence for the safety and efficacy of G-
CSF treatments has been published since the last class review in October 2022.• In …
CSF treatments has been published since the last class review in October 2022.• In …